Global /China /Healthcare /Drug Manufacturers - General /301201

ChengDa Pharmaceuticals Co., Ltd.

301201

• SHE: 301201 • Delayed

41.24CNY 0%

6.09 USD

As of 14 June 2026, ChengDa Pharmaceuticals Co., Ltd. has a market cap of $921.65M USD, ranking #11169 globally and #3203 in China. It ranks #1011 in the Healthcare sector, and #379 in the Drug Manufacturers - General industry.

Global Rank

11169

Country Rank

3203

Sector Rank

1011

Industry Rank

379

Key Stats

Market Cap

$921.65MUSD

6.25B CNY

Enterprise Value

$789.47MUSD

5.34B CNY

Revenue (TTM)

$67.64MUSD

458.3M CNY

EBITDA (TTM)

$15.33MUSD

103.74M CNY

Net Income (TTM)

-$520.05KUSD

-3.52M CNY

EBITDA Margin

23%

Profit Margin

-0.8%

PS Ratio

13.6

PB Ratio

3.0

EV/EBITDA

51.5

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Gang Lu open_in_new

Employees

656

Founded

1980

Website

chengdapharm.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	3.2%	-11%	3.3%	27%	1.3%	102%	44%	-32%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	301201 诚达药业股份有限公司 Class A ISIN: CNE100005766 Shares Out.: Shares Outstanding: 151.469M¹ Shares Float: 120.106M² TV: TradingView: SZSE: 301201 SA: Stock Analysis: SHE: 301201 YF: Yahoo Finance: 301201.SZ GF: Google Finance: SHE: 301201 BA: Barron's: 301201 MS: Morningstar: XSHE: 301201	41.24 CNY	TV: TradingView: SZSE: 301201 SA: Stock Analysis: SHE: 301201 YF: Yahoo Finance: 301201.SZ GF: Google Finance: SHE: 301201 BA: Barron's: 301201 MS: Morningstar: XSHE: 301201

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About ChengDa Pharmaceuticals Co., Ltd.

ChengDa Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, chemical ingredients, and food and feed additives in China and internationally. It offers process research and development, process optimization, quality and stability research, customized production and other services for pharmaceutical intermediates and APIs; and food and feed additives, such as L-carnitine and L-carnitine tartrate. The company also provides bulk drug products, including urogenital, nervous system, blood and hematopoietic organs, muscular system, digestive tract and metabolism, antineoplastic and immunomodulators; and pharmaceutical intermediates comprising drug intermediates for blood and hematopoietic organs, drug intermediates in digestive tract and metabolism, and nervous system drug intermediates. ChengDa Pharmaceuticals Co., Ltd. was founded in 1980 and is based in Jiaxing, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.85B 364.89B CNY 6K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.64B 336.36B CNY 5K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 3K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 2K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.51B 111.89B CNY 2K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 2K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 83K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 59K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 39K%	97.4	United States
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 35K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 31K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 30K%	20.5	Switzerland

chevron_leftBack